10,629 Shares in Exscientia plc (NASDAQ:EXAI) Bought by Vanguard Personalized Indexing Management LLC

Vanguard Personalized Indexing Management LLC purchased a new position in shares of Exscientia plc (NASDAQ:EXAI) during the second quarter, Holdings Channel.com reports. The fund purchased 10,629 shares of the company’s stock, valued at approximately $54,000.

Other hedge funds also recently added to or reduced their stakes in the company. GAMMA Investing LLC boosted its position in shares of Exscientia by 112.1% during the first quarter. GAMMA Investing LLC now owns 4,356 shares of the company’s stock worth $25,000 after buying an additional 2,302 shares during the period. China Universal Asset Management Co. Ltd. boosted its position in Exscientia by 76.8% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 9,274 shares of the company’s stock worth $53,000 after acquiring an additional 4,029 shares during the period. EntryPoint Capital LLC grew its stake in shares of Exscientia by 22.8% in the first quarter. EntryPoint Capital LLC now owns 31,171 shares of the company’s stock worth $178,000 after purchasing an additional 5,784 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in shares of Exscientia by 108.8% during the second quarter. Bank of New York Mellon Corp now owns 388,459 shares of the company’s stock valued at $1,981,000 after purchasing an additional 202,377 shares during the period. Finally, Federated Hermes Inc. bought a new stake in shares of Exscientia during the second quarter valued at about $115,000. 41.58% of the stock is currently owned by institutional investors.

Exscientia Price Performance

Shares of Exscientia stock opened at $4.62 on Wednesday. Exscientia plc has a 52 week low of $3.80 and a 52 week high of $7.91. The company has a current ratio of 5.93, a quick ratio of 5.93 and a debt-to-equity ratio of 0.06. The stock has a market cap of $557.89 million, a PE ratio of -3.52 and a beta of 0.86. The company’s 50-day moving average price is $5.17 and its two-hundred day moving average price is $5.15.

Exscientia (NASDAQ:EXAI) last released its earnings results on Thursday, August 15th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.05). The business had revenue of $5.60 million for the quarter. Exscientia had a negative net margin of 620.99% and a negative return on equity of 37.56%. As a group, sell-side analysts anticipate that Exscientia plc will post -1.25 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have commented on EXAI. TD Cowen reissued a “hold” rating on shares of Exscientia in a research note on Friday, August 9th. Barclays reissued an “equal weight” rating and set a $5.00 target price on shares of Exscientia in a report on Tuesday, August 13th.

Exscientia Company Profile

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy.